Memantine for alzheimer disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 1 Oct 2021: Trial registered, NCT05063851
  2. 11 Oct 2021: Trial started, NCT05063851

The trials

NCT05063851: The Use of Memantine for Prevention of Alzheimer's Disease

State
Under way
Phase
Phase 2
People
32 planned
Started
11 Oct 2021
Primary completion
Dec 2026
Arms
Memantine hydrochloride
Results
None posted
  1. 1 Oct 2021: Trial registered
  2. 11 Oct 2021: Trial started

NCT05430867: Efficacy and Safety of Memantine and Sodium Oligomannate in Patients With Moderate to Severe Alzheimer's Disease

State
State not given
Phase
Phase 4
People
150 planned
Started
1 Jul 2022
Primary completion
1 Jul 2024
Arms
Memantine monotherapy group
Results
None posted
  1. 24 Jun 2022: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Memantine Hydrochloride Tablets, Memantine Oral Tablet, Nemdatine.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.